Human Genome Sciences (HGSI)
Human Genome Sciences Cash and ST Investments: 471.80M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
HGSI Cash and ST Investments Rankings
| Overall | 80th percentile | 866 of 4365 |
| Sector | 87th percentile | 61 of 504 in Healthcare |
| Industry | 93rd percentile | 11 of 160 in Biotechnology |
HGSI Cash and ST Investments Range, Past 5 Years
| Minimum | 37.94M | Dec 2008 |
| Maximum | 719.20M | Dec 2009 |
| Average | 330.96M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these HGSI related companies
HGSI News
@Glopolon I think I'll wait a bit more on $SPPI. Hope it doesn't run away from me like $HGSI did.
about 5 days ago by mitrado
about 5 days ago by mitrado
@GPrime $ARNA You could do what GSK is trying to do with $HGSI and buy if and when the share price falls back down again
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
genomics have been running for awhile now since $HGSI news and now $ROSG. $ILMN denied Roche buyout but who r next most likely targets?
about 5 days ago by epime7heus
about 5 days ago by epime7heus
Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
May 24, 11:25AM Street Insider
May 24, 11:25AM Street Insider
$GSK reacts to $HGSI poison pill. Stubborn, or what? It seems they do not want to get pushed or pulled.
about 6 days ago by OysterX
about 6 days ago by OysterX
GlaxoSmithKline Amends HGS Tender Offer to Address Poison Pill, Requires HGS to Redeem Pill
May 23, 8:37AM Benzinga
May 23, 8:37AM Benzinga
I'm still somewhat numb after failing to buy $HGSI the day before it doubled. I was waiting for it to touch $7.00... What a fool, eh?
about 7 days ago by mitrado
about 7 days ago by mitrado
Glaxo (GSK) Comments on Human Genome (HGSI) Bid Rejection; Will Continue with $13/Share Tender
May 17, 1:17PM Street Insider
May 17, 1:17PM Street Insider
Human #Genome $HGSI board adopts 'poison pill' antitakeover plan, rejects #GlaxoSmithKline $2.6B bid: http://stks.co/3sQY
about 12 days ago by TMXmoney
about 12 days ago by TMXmoney
Still think that $GSK will not succeed with $HGSI takeover at 13/share. They will increase the offer price, but probably not above 15.
about 12 days ago by OysterX
about 12 days ago by OysterX
Human Genome Sciences (HGSI) Unanimously Rejects GlaxoSmithKline (GSK) Offer
May 17, 7:06AM Street Insider
May 17, 7:06AM Street Insider
Human Genome Sciences Announces Adoption of Short-Term Stockholder Rights Plan
May 17, 7:03AM Benzinga
May 17, 7:03AM Benzinga
Barclays Maintains an 'Equalweight' on Human Genome Sciences (HGSI); Looking At $15/Share For GSK To Seal The Deal
May 14, 3:58PM Street Insider
May 14, 3:58PM Street Insider
$HGSI every1 on here should buy RXII-going to $1 soon this company does almost same as HGSI~disease associated genes
about 15 days ago by unusual7
about 15 days ago by unusual7
$HGSI lots of buying there end of day. Makes me feel like someone knows something for weekend deal. I was wrong shorting. Glad out.
about 18 days ago by tweetingstocks
about 18 days ago by tweetingstocks
$HGSI closing short for now $300 lose. Price is moving the wrong way and not holding over the weekend. Deals get done on weekends :)
about 18 days ago by tweetingstocks
about 18 days ago by tweetingstocks
$HGSI taking a short position. This latest bid I'm sure will scare some people out as it should.
about 19 days ago by tweetingstocks
about 19 days ago by tweetingstocks
$HGSI better hope someone else comes in, because now GSK only values them at $13.
about 19 days ago by tweetingstocks
about 19 days ago by tweetingstocks
GlaxoSmithKline commences tender offer to acquire Human Genome Sciences for $13 per Share
May 10, 8:25AM Benzinga
May 10, 8:25AM Benzinga
Breakfast Links | via @PointsnFigures http://stks.co/3jto $AMZN $GSK $HGSI $ZNGA
about 20 days ago by STNet
about 20 days ago by STNet
That's a surprise. $GSK goes hostile with $HGSI offer at 13. Did not expect that and am curious whether HGSI has something up its sleeve.
about 21 days ago by OysterX
about 21 days ago by OysterX
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HGSI | 13.81 | +0.20 | +1.47% | 2.708B |
| HGSH | 0.70 | -0.08 | -10.26% | 31.54M |
| HGR | 22.05 | +0.69 | +3.23% | 727.09M |
| HGIC | 59.94 | +0.00 | +0.00% | 1.635B |
| HGI | 15.41 | +0.18 | +1.20% | |
| HGG | 11.09 | +0.22 | +2.02% | 404.80M |
| HGEM | 17.67 | +0.00 | +0.00% | |
| HFWA | 13.77 | +0.34 | +2.53% | 207.76M |
| HFC | 30.34 | +0.00 | +0.00% | 6.318B |
| HFBC | 7.05 | -0.10 | -1.47% | 55.62M |